Dear Editor,

Congenital prekallikrein (PK) deficiency is a rare autosomal recessive coagulation disorder characterized as either type I or II. Type I is associated with a decrease or absence of PK antigen and activity, while type II is associated with low PK activity and varying antigen levels [1]. PK deficiency presents with prolonged isolated activated partial thromboplastin time (aPTT). Other potential causes of isolated aPTT prolongation without bleeding include presence of lupus anticoagulant (LA) and deficiencies of contact phase factors, including factor XII (FXII) and high molecular-weight kininogen (HMWK) [2]. LA and FXII levels can be easily assessed with laboratory tests, whereas PK and HMWK levels and activity are more challenging to assess. Pre-incubating PK deficient plasma with a surface activator in the aPTT reagent, which causes FXII autoactivation, can bypass the fast PK to kallikrein reaction and kallikrein-mediated FXII activation [3]. During pre-incubation in the aPTT assay, only PK deficiency causes aPTT shortening, a finding that can differentiate PK and HMWK deficiencies. We present the first case, to our knowledge, of congenital PK deficiency in Korea.

This study was approved by the Institutional Review Board of Seoul National University Hospital (No. 1304-085-481), Seoul, Korea. A four-year-old Korean male with tonsil hypertrophy was scheduled to undergo an elective tonsillectomy at Seoul National University Hospital. During the pre-operative evaluation, a marked prolonged aPTT and normal prothrombin time were noted (Table 1). The patient was taking no medication. Personal and family history revealed no bleeding tendency. Mixing test for aPTT showed complete correction, and coagulation factors FVIII, FIX, FXI, and FXII of the intrinsic pathway were all normal. LA was negative. Upon suspicion of PK deficiency, aPTT assays with various pre-incubation times were performed; the aPTT of samples pre-incubated with an aPTT reagent was dramatically shortened (Fig. 1A).

PK antigen level measured by ELISA (SEB801Hu, Cloud-Clone Corporation, Houston, TX, USA) was 0.38 ng/mL, and plasma kallikrein activity measured chromogenically (#K997-100, Biovis, Milpitas, CA, USA) was undetectable. Genomic DNA was extracted from peripheral blood. PCR and direct sequencing of the KLKB1 gene, which encodes prekallikrein, were performed to amplify the coding and flanking regions from exons 2 to 15 [4]. Two variants were detected when comparing the sequence exon with the reference sequence (GenBank Accession Number NM_000892). We detected a novel substitution (c.1198G>T) in exon 11, leading to premature termination of KLKB1 (p.Gly400Ter) (Fig. 1B). This was considered a pathogenic variant according to the 2015 American College of Medical Genetics and Genomics and Association guidelines based on the following factors:

© Korean Society for Laboratory Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
PVS1 (predicted null variant), PM2 (absent in population data, Exome Aggregation Consortium, http://exac.broadinstitute.org/), and PP4 (patient’s phenotype specific for gene) [5]. A missense mutation (c.1259G>A, p.Gly420Glu) was also found in exon 11 (Fig. 1C), which had been detected previously in a family with PK deficiency and caused the loss of PK activity [6].

Functional predictions of the two variants performed using MutationTaster (http://www.mutationtaster.org) revealed them as “disease causing”; therefore, the patient was diagnosed as having type I congenital PK deficiency. He underwent tonsillectomy without any bleeding complication.

Several studies have examined genetic mutations leading to PK deficiency [7-9]. Mutations in exons 11 and 14, which encode the catalytic domain of the light chain, are frequently observed [7]. In our case, a compound heterozygous mutation was identified in exon 11, as in other cases [7-9]. Structural analysis showed that the mutants do not contain the catalytic domain of the light chain encoded by exons 11–15. Thus, these mutations may reduce the activity of PK.

Although PK deficiency usually does not increase bleeding tendency, a minor bleeding tendency has been observed [8]. Thrombosis has been reported in fewer than 10 patients with PK deficiency [10]. While FXII deficiency does not cause thrombosis due to defective FXII-induced coagulation activation, PK deficiency may lead to thrombosis, but the mechanism is unclear [7-10]. These complications tend to be more commonly reported in type I PK deficiency.

In conclusion, we report a case of congenital PK deficiency with typical results in pre-incubation aPTT assays, caused by a novel pathogenic variant. The possibility of PK deficiency should be considered when treating a patient with isolated aPTT prolongation. The PK deficient patient requires follow-up assessment for the potential complications and should be aware of the

Table 1. Patient’s laboratory results

| Parameter                  | Result | Reference range |
|----------------------------|--------|-----------------|
| CBC                        |        |                 |
| WBC count (× 10^9/L)       | 5.83   | 6–17           |
| Hb (g/L)                   | 135    | 110–138        |
| Platelets (× 10^9/L)       | 281    | 210–490        |
| Coagulation assay          |        |                 |
| PT (sec)                   | 12.1   | 9.8–12.9       |
| aPTT (sec)                 | 222    | 26.7–37.6      |
| Fibrinogen (mg/dL)         | 201    | 192–411        |
| aPTT mixing assay          |        |                 |
| Immediate (sec)            | 34.0   | 26.7–37.6      |
| 1 hour incubation (sec)    | 33.3   | 26.7–37.6      |
| Factor activity assay      |        |                 |
| Factor VIII                | 1.09   | 0.52–1.90      |
| Factor IX                  | 0.73   | 0.74–1.37      |
| Factor XI                  | 0.96   | 0.60–1.50      |
| Factor XII                 | 0.77   | 0.60–1.50      |
| Prekallikrein assay        |        |                 |
| Prekallikrein antigen (ng/mL) | 0.38 | 8.55–13.65    |
| Kallikrein activity (U/L)  | <10    | 161.1–233.3   |

Abbreviations: Hb, hemoglobin; CBC, complete blood count; WBC, white blood cell; PT, prothrombin time; aPTT, activated partial thromboplastin time.

Fig. 1. Results from prekallikrein assays. (A) The patient’s and normal plasma were pre-incubated with an activated partial thromboplastin time (aPTT) reagent containing silica activator (SynthASil, Instrumentation Laboratory, Miami, USA) for various times, and clotting times were measured after addition of calcium chloride. Patient plasma pre-incubated with the aPTT reagent showed significant shortening of aPTT. (B) Direct sequencing of KLKB1 showed a c.1198G>T (between red lines) nonsense mutation in exon 11, resulting in premature termination at the 400th amino acid (p.Gly400Ter). (C) Direct sequencing of KLKB1 also showed a c.1259G>A (between red lines) missense mutation in exon 11, leading to the conversion of glycine to glutamine at the 420th amino acid (p.Gly420Glu).
risk of unnecessary transfusion.

**Authors’ Disclosures of Potential Conflicts of Interest**

The authors have no conflicts of interest to disclose.

**Acknowledgments**

This work (2016R1A2B4015571) was supported by the Mid-Career Researcher Program through the NRF grant funded by the Korea government (Ministry of Science, ICT and Future Planning).

**REFERENCES**

1. Girolami A, Scarpato P, Candeo N, Lombardi AM. Congenital prekallikrein deficiency. Expert Rev Hematol 2010;3:685-95.
2. Chng WJ, Sum C, Kuperan P. Causes of isolated prolonged activated partial thromboplastin time in an acute care general hospital. Singapore Med J 2005;46:450-6.
3. Asmis LM, Sulzer I, Furlan M, Lämmle B. Prekallikrein deficiency; the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. Thromb Res 2002;105:463-70.
4. Yu H, Anderson P, Freedman B, Rich S, Bowden D. Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease. Genomics 2000;69:225-34.
5. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24.
6. Shigekayo T, Fujino O, Kanagawa Y, Matsumoto T. Prekallikrein (PK) Toku-shima: PK deficiency caused by a Gly401-->Glu mutation. J Thromb Haemost 2003;1:1314-6.
7. Girolami A, Ferrari S, Cosi E, Lombardi AM. A structure-function analysis in patients with prekallikrein deficiency. Hematology 2018;23:346-50.
8. Girolami A CE, Ferrari S, Santarossa C. Critical analysis of the patients with congenital prekallikrein deficiency and a “purported” bleeding tendency. J Mol Genet Med 2017;1:9.
9. Girolami A, Ferrari S, Cosi E, Sambado L, Girolami B. Prevalence of hypertension and its complications in congenital prekallikrein deficiency: analysis of all reported cases and clinical significance. Blood Coagul Fibrinolysis 2015;26:560-3.
10. Girolami A, Allemand E, Bertozi I, Candeo N, Marun S, Girolami B. Thrombotic events in patients with congenital prekallikrein deficiency: a critical evaluation of all reported cases. Acta Haematol 2010;123:210-4.